(ABUS) Arbutus Biopharma - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 839m USD | Total Return: 28.9% in 12m

Stock Hepatitis B, RNAi, Immune Response
Total Rating 27
Risk 26
Buy Signal -0.27
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 839m
Avg Trading Vol: 8.52M USD
ATR: 5.63%
Peers RS (IBD): 34.8
Risk 5d forecast
Volatility47.6%
Rel. Tail Risk-8.49%
Reward TTM
Sharpe Ratio0.68
Alpha11.24
Character TTM
Beta0.925
Beta Downside1.890
Drawdowns 3y
Max DD43.67%
CAGR/Max DD0.34
EPS (Earnings per Share) EPS (Earnings per Share) of ABUS over the last years for every Quarter: "2021-03": -0.21, "2021-06": -0.23, "2021-09": -0.24, "2021-12": -0.15, "2022-03": -0.11, "2022-06": -0.1, "2022-09": -0.12, "2022-12": -0.14, "2023-03": -0.1, "2023-06": -0.1, "2023-09": -0.12, "2023-12": -0.12, "2024-03": -0.1, "2024-06": -0.11, "2024-09": -0.09, "2024-12": -0.0999, "2025-03": -0.1816, "2025-06": 0.01, "2025-09": -0.04, "2025-12": -0.0137,
EPS CAGR: 23.10%
EPS Trend: 50.9%
Last SUE: 0.70
Qual. Beats: 0
Revenue Revenue of ABUS over the last years for every Quarter: 2021-03: 2.113, 2021-06: 2.329, 2021-09: 3.34, 2021-12: 3.206, 2022-03: 12.581, 2022-06: 14.241, 2022-09: 5.952, 2022-12: 6.245, 2023-03: 6.687, 2023-06: 4.651, 2023-09: 4.658, 2023-12: 2.145, 2024-03: 1.532, 2024-06: 1.726, 2024-09: 1.339, 2024-12: 1.574, 2025-03: 1.764, 2025-06: 10.739, 2025-09: 0.529, 2025-12: 1.051,
Rev. CAGR: -48.42%
Rev. Trend: -74.7%
Last SUE: -1.36
Qual. Beats: 0
Risks
Technicals: choppy
Description: ABUS Arbutus Biopharma March 05, 2026

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases in the United States.

Its primary pipeline targets chronic Hepatitis B virus (HBV) with two product candidates: Imdusiran, an RNAi therapeutic in Phase 1 and 2a trials, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b trials. Biopharmaceutical companies typically incur significant R&D costs and lengthy development timelines before product commercialization.

The company also has a licensing agreement with Alnylam Pharmaceuticals, Inc. for LNP delivery technology. This business model relies on intellectual property and successful clinical trial outcomes.

For more detailed financial and operational data, ValueRay offers comprehensive company profiles.

Headlines to Watch Out For
  • Imdusiran clinical trial results impact stock
  • AB-101 trial progress drives investor sentiment
  • Licensing revenue from Alnylam supports operations
  • Future drug approvals are critical for revenue growth
Piotroski VR‑10 (Strict, 0-10) 1.0
Net Income: -33.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.42 > 0.02 and ΔFCF/TA 7.48 > 1.0
NWC/Revenue: 628.1% < 20% (prev 1.81k%; Δ -1.18k% < -1%)
CFO/TA -0.42 > 3% & CFO -39.6m > Net Income -33.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 15.73 > 1.5 & < 3
Outstanding Shares: last quarter (191.6m) vs 12m ago 0.86% < -2%
Gross Margin: 36.15% > 18% (prev -2.98%; Δ 3.91k% > 0.5%)
Asset Turnover: 12.44% > 50% (prev 4.69%; Δ 7.76% > 0%)
Interest Coverage Ratio: -384.6 > 6 (EBITDA TTM -36.9m / Interest Expense TTM 97.0k)
Altman Z'' -15.00
A: 0.93 (Total Current Assets 94.5m - Total Current Liabilities 6.01m) / Total Assets 94.6m
B: -14.59 (Retained Earnings -1.38b / Total Assets 94.6m)
C: -0.33 (EBIT TTM -37.3m / Avg Total Assets 113.2m)
D: -0.37 (Book Value of Equity -6.74m / Total Liabilities 18.0m)
Altman-Z'' Score: -44.03 = D
Beneish M -0.04
DSRI: 0.32 (Receivables 1.75m/2.41m, Revenue 14.1m/6.17m)
GMI: 1.00 (fallback, negative margins)
AQI: 5.32 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 2.28 (Revenue 14.1m / 6.17m)
TATA: 0.06 (NI -33.5m - CFO -39.6m) / TA 94.6m)
Beneish M-Score: -0.04 (Cap -4..+1) = D
What is the price of ABUS shares? As of April 01, 2026, the stock is trading at USD 4.50 with a total of 2,063,276 shares traded.
Over the past week, the price has changed by +4.41%, over one month by -3.64%, over three months by -6.44% and over the past year by +28.94%.
Is ABUS a buy, sell or hold? Arbutus Biopharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ABUS.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ABUS price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 5.6 24.9%
Analysts Target Price 5.6 24.9%
ABUS Fundamental Data Overview March 30, 2026
P/E Forward = 10.2459
P/S = 59.547
P/B = 10.573
Revenue TTM = 14.1m USD
EBIT TTM = -37.3m USD
EBITDA TTM = -36.9m USD
Long Term Debt = 746k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 547k USD (from shortTermDebt, last quarter)
Debt = 4.19m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.8m USD (from netDebt column, last quarter)
Enterprise Value = 751.3m USD (838.6m + Debt 4.19m - CCE 91.5m)
Interest Coverage Ratio = -384.6 (Ebit TTM -37.3m / Interest Expense TTM 97.0k)
EV/FCF = -18.95x (Enterprise Value 751.3m / FCF TTM -39.6m)
FCF Yield = -5.28% (FCF TTM -39.6m / Enterprise Value 751.3m)
 FCF Margin = -281.5% (FCF TTM -39.6m / Revenue TTM 14.1m)
 Net Margin = -237.9% (Net Income TTM -33.5m / Revenue TTM 14.1m)
 Gross Margin = 36.15% ((Revenue TTM 14.1m - Cost of Revenue TTM 8.99m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.94 (Enterprise Value 751.3m / Total Assets 94.6m)
Interest Expense / Debt = 0.43% (Interest Expense 18.0k / Debt 4.19m)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.5m (EBIT -37.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.73 (Total Current Assets 94.5m / Total Current Liabilities 6.01m)
Debt / Equity = 0.05 (Debt 4.19m / totalStockholderEquity, last quarter 76.6m)
 Debt / EBITDA = 0.37 (negative EBITDA) (Net Debt -13.8m / EBITDA -36.9m)
 Debt / FCF = 0.35 (negative FCF - burning cash) (Net Debt -13.8m / FCF TTM -39.6m)
 Total Stockholder Equity = 79.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.60% (Net Income -33.5m / Total Assets 94.6m)
RoE = -42.39% (Net Income TTM -33.5m / Total Stockholder Equity 79.0m)
RoCE = -46.77% (EBIT -37.3m / Capital Employed (Equity 79.0m + L.T.Debt 746k))
 RoIC = -37.30% (negative operating profit) (NOPAT -29.5m / Invested Capital 79.0m)
 WACC = 9.20% (E(838.6m)/V(842.8m) * Re(9.24%) + D(4.19m)/V(842.8m) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.65%
 [DCF] Fair Price = unknown (Cash Flow -39.6m)
 EPS Correlation: 50.88 | EPS CAGR: 23.10% | SUE: 0.70 | # QB: 0
Revenue Correlation: -74.73 | Revenue CAGR: -48.42% | SUE: -1.36 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.06 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.23 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+1 | Growth EPS=+2.7% | Growth Revenue=-86.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
Additional Sources for ABUS Stock Fund Manager Positions: Dataroma · Stockcircle